Novartis will pay the biotechnology company $150 million upfront to gain rights to an early-stage molecular glue degrader aimed at immune-mediated diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,